ACHFF (Arch Biopartners) EV-to-EBITDA : -71.35 (As of Dec. 11, 2024)

View and export this data going back to 2009. Start your Free Trial

What is Arch Biopartners EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Arch Biopartners's enterprise value is $92.54 Mil. Arch Biopartners's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.30 Mil. Therefore, Arch Biopartners's EV-to-EBITDA for today is -71.35.

The historical rank and industry rank for Arch Biopartners's EV-to-EBITDA or its related term are showing as below:

ACHFF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -119.1 Med: -33.75 Max: -13.92
Current: -71.35

During the past 13 years, the highest EV-to-EBITDA of Arch Biopartners was -13.92. The lowest was -119.10. And the median was -33.75.

ACHFF's EV-to-EBITDA is ranked worse than
100% of 447 companies
in the Biotechnology industry
Industry Median: 9.29 vs ACHFF: -71.35

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-12-11), Arch Biopartners's stock price is $1.35. Arch Biopartners's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.025. Therefore, Arch Biopartners's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).

Arch Biopartners EV-to-EBITDA Historical Data

The historical data trend for Arch Biopartners's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners EV-to-EBITDA Chart

Arch Biopartners Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

EV-to-EBITDA

Get a 7-Day Free Trial

-30.71

-19.32

-124.07

-174.27

-24.40

Arch Biopartners Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBITDA	Get a 7-Day Free Trial															-41.32	-34.43	-24.40	-62.05	-83.49

Competitive Comparison of Arch Biopartners's EV-to-EBITDA

For the Biotechnology subindustry, Arch Biopartners's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arch Biopartners's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Biopartners's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Arch Biopartners's EV-to-EBITDA falls into.

Arch Biopartners EV-to-EBITDA Calculation

Arch Biopartners's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	92.538	/	-1.297
	=	-71.35

Arch Biopartners's current Enterprise Value is $92.54 Mil.
Arch Biopartners's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.30 Mil.

Arch Biopartners (OTCPK:ACHFF) EV-to-EBITDA Explanation

Arch Biopartners's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	1.35	/	-0.025
	=	At Loss

Arch Biopartners's share price for today is $1.35.
Arch Biopartners's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.025.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Arch Biopartners EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Arch Biopartners's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Arch Biopartners Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (OTCPK:ACHFF) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

ARCH:Canada

Address

545 King Street West, Toronto, ON, CAN, M5V 1M1

Website

https://www.archbiopartners.com

Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.